Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Rhabdomyosarcoma
The commonest soft-tissue sarcoma of childhood; PAX3::FOXO1 fusion-positive and metastatic disease do worst.
Live from ClinicalTrials.gov, fetched 2026-11-12 13:50 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
85
Phase 1 to 3, interventional
For relapsed or refractory disease
44%
37 trial titles name relapsed, refractory or recurrent disease
Led by industry
12%
10 trials with a company as lead sponsor
6 of the 85 rhabdomyosarcoma trials are Phase 3; 4 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of rhabdomyosarcoma (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 25 of 85 trials name no segment and are listed as Untagged.
Segment:All1L1L · Advanced or metastatic1L · Locally advanced1L · Maintenance1L · Relapsed or refractoryAdvanced or metastaticLocally advancedMaintenanceRelapsed or refractoryUntagged
Modality:AllAntibodyAntibody-drug conjugateCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Ivocizumab Fudan University | Advanced or metastatic | Antibody | Ph2 | NCT06683846 |
| Nivolumab Injectable Product Baylor College of Medicine | Advanced or metastatic | Antibody | Ph1 | NCT04995003 |
| Pembrolizumab Injectable Product Baylor College of Medicine | Advanced or metastatic | Antibody | Ph1 | NCT04995003 |
Assets over time
85 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Cyclophosphamide | National Cancer Institute (NCI) | |
| Right Arm treated with Active Re-Q Pro-Longevity Serum and Intense Pulsed Light Therapy | Goldman, Butterwick, Fitzpatrick and Groff | |
| Doxorubicin | National Cancer Institute (NCI) | |
| Vincristine | St. Jude Children's Research Hospital | |
| Ensartinib | National Cancer Institute (NCI) | |
| Palbociclib | Pfizer | |
| PEEL-224 | Theodore Laetsch | |
| Cabozantinib | National Cancer Institute (NCI) | |
| Larotrectinib Sulfate | National Cancer Institute (NCI) | |
| Silmitasertib | Milton S. Hershey Medical Center | |
| Atezolizumab | University of Texas Southwestern Medical Center | |
| dasatinib | City of Hope Medical Center | |
| Tipifarnib | National Cancer Institute (NCI) | |
| Erdafitinib | National Cancer Institute (NCI) | |
| Selpercatinib | National Cancer Institute (NCI) | |
| pH Low Insertion Peptide-exatecan Conjugate CBX-12 | Children's Oncology Group | |
| Ulixertinib | National Cancer Institute (NCI) | |
| Daraxonrasib | Children's Oncology Group | |
| Pazopanib | St. Jude Children's Research Hospital | |
| Ivosidenib | National Cancer Institute (NCI) | |
| Zoledronic acid | University of Florida | |
| Methionine | St. Jude Children's Research Hospital | |
| filgrastim | Memorial Sloan Kettering Cancer Center | |
| Onivyde | St. Jude Children's Research Hospital | |
| Doxorubicin Hydrochloride Liposome+Irinotecan | Sun Yat-sen University | |
| Peptide vaccine IPX | University Hospital Tuebingen | |
| Samotolisib | National Cancer Institute (NCI) | |
| Tazemetostat | National Cancer Institute (NCI) | |
| nab-Paclitaxel | H. Lee Moffitt Cancer Center and Research Institute | |
| PEN-866 | National Cancer Institute (NCI) |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07686198 Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms Single-country: United States (1 site) Decision brief → | Ph2/Ph3 | Goldman, Butterwick, Fitzpatrick and Groff | not yet recruiting | 2026-07-07 | 2026-11-10 |
| NCT07466316 A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) 2 countries, 99% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | recruiting | 2026-03-12 | 2031-03-31 |
| NCT05304585 Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma 4 countries, 92% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | recruiting | 2022-03-31 | 2030-06-30 |
| NCT04994132 A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma 5 countries, 91% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | active not recruiting | 2021-08-06 | 2026-06-30 |
| NCT02567435 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma 5 countries, 93% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2015-10-05 | 2023-06-30 |
| NCT02180867 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery 3 countries, 96% of sites in the US Decision brief → | Ph2/Ph3 | National Cancer Institute (NCI) | completed | 2014-07-03 | 2019-06-30 |
| NCT07830667 A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat No sites listed Decision brief → | Ph1/Ph2 | Children's Oncology Group | not yet recruiting | 2026-09-21 | 2033-06-30 |
| NCT07819838 Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations No sites listed Decision brief → | Ph1/Ph2 | Children's Oncology Group | not yet recruiting | 2026-09-15 | 2032-04-09 |
| NCT07444918 Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors No sites listed Decision brief → | Ph2 | Tianjin Medical University Cancer Institute and Hospital | not yet recruiting | 2026-03-03 | 2027-12-01 |
| NCT07355855 A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma Single-country: China (1 site) Decision brief → | Ph2 | Fudan University | not yet recruiting | 2026-01-21 | 2029-01 |
| PROSARC-2 · NCT07173972 Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Single-country: Norway (2 sites) Decision brief → | Ph2 | Oslo University Hospital | recruiting | 2025-09-15 | 2029-01-26 |
| PROSARC-1 · NCT07169344 Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma Single-country: Norway (4 sites) Decision brief → | Ph2 | Oslo University Hospital | recruiting | 2025-09-11 | 2029-01-26 |
| ALTER-02 · NCT07137884 Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children Single-country: China (1 site) Decision brief → | Ph2 | Sun Yat-sen University | not yet recruiting | 2025-08-22 | 2028-10-30 |
| PEEL-224 · NCT06721689 PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors Single-country: United States (7 sites) Decision brief → | Ph1/Ph2 | Theodore Laetsch | recruiting | 2024-12-06 | 2030-04 |
| NCT06709495 Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | David S Shulman, MD | recruiting | 2024-11-29 | 2028-11-01 |
| NCT06683846 Ivonescimab in the Treatment of Multiple Advanced Tumors Single-country: China (1 site) Decision brief → | Ph2 | Fudan University | recruiting | 2024-11-12 | 2027-11-30 |
| NCT06625190 Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | University of Florida | recruiting | 2024-10-03 | 2030-02 |
| NCT06541262 Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors 2 countries, 93% of sites in the US Decision brief → | Ph1/Ph2 | Milton S. Hershey Medical Center | recruiting | 2024-08-07 | 2030-11-01 |
| NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer 6 countries, 30% of sites in the US Decision brief → | Ph1/Ph2 | GlaxoSmithKline | active not recruiting | 2024-07-26 | 2026-10-13 |
| NCT06277154 MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma Single-country: China (1 site) Decision brief → | Ph2 | HRYZ Biotech Co. | recruiting | 2024-02-26 | 2026-02 |
| NCT06239272 NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Single-country: United States (7 sites) Decision brief → | Ph1/Ph2 | St. Jude Children's Research Hospital | recruiting | 2024-02-02 | 2034-06 |
| PerVision · NCT06094101 Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) Single-country: Germany (4 sites) Decision brief → | Ph1/Ph2 | University Hospital Tuebingen | recruiting | 2023-10-23 | 2027-06 |
| NCT06023641 Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease Single-country: United States (3 sites) Decision brief → | Ph2 | St. Jude Children's Research Hospital | recruiting | 2023-09-05 | 2034-10 |
| NCT05457829 Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study Single-country: China (1 site) Decision brief → | Ph2 | Sun Yat-sen University | recruiting | 2022-07-14 | 2026-06-30 |
| NCT05199584 A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations Single-country: United States (16 sites) Decision brief → | Ph2 | Endeavor Biomedicines, Inc. | completed | 2022-01-20 | 2024-02-20 |
| NCT05135975 A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Nationwide Children's Hospital | recruiting | 2021-11-26 | 2026-07 |
| NCT05071209 Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors 2 countries, 97% of sites in the US Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | active not recruiting | 2021-10-08 | 2024-09-30 |
| NCT04901702 Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma 2 countries, 70% of sites in the US Decision brief → | Ph1/Ph2 | St. Jude Children's Research Hospital | recruiting | 2021-05-25 | 2026-12-31 |
| NCT04890093 Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | suspended | 2021-05-18 | 2026-12-31 |
| NCT04796012 VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors Single-country: United States (7 sites) Decision brief → | Ph1/Ph2 | University of Texas Southwestern Medical Center | active not recruiting | 2021-03-12 | 2027-01 |
| NCT04388839 Evolutionary Therapy for Rhabdomyosarcoma Single-country: United States (18 sites) Decision brief → | Ph2 | H. Lee Moffitt Cancer Center and Research Institute | active not recruiting | 2020-05-14 | 2026-08 |
| NCT04320888 Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial 3 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-03-25 | 2024-09-30 |
| NCT04284774 Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial 2 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-02-26 | 2024-03-31 |
| NCT04238819 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma 8 countries, 48% of sites in the US Decision brief → | Ph1/Ph2 | Eli Lilly and Company | completed | 2020-01-23 | 2024-03-15 |
| NCT04195555 Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) 3 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2019-12-12 | 2025-03-31 |
| NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors 13 countries, 67% of sites in the US Decision brief → | Ph2 | Pfizer | completed | 2018-10-17 | 2024-08-26 |
| NCT03698994 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2018-10-09 | 2022-03-31 |
| NCT03526250 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2018-05-16 | 2023-03-31 |
| NCT03213704 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2024-09-30 |
| NCT03213652 Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) 4 countries, 97% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2025-09-30 |
| NCT03213678 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2023-09-30 |
| NCT03213665 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2022-03-31 |
| NCT03210714 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-07 | 2023-09-30 |
| NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) 4 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-05-16 | 2025-03-31 |
| NCT02945800 Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Single-country: United States (14 sites) Decision brief → | Ph2 | H. Lee Moffitt Cancer Center and Research Institute | completed | 2016-10-26 | 2024-11-19 |
| NCT02867592 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Single-country: United States (142 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2016-08-16 | 2021-06-30 |
| AflacST1502 · NCT02574728 Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Emory University | active not recruiting | 2015-10-14 | 2026-06 |
| NCT01871766 Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy Single-country: United States (4 sites) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2013-06-07 | 2026-12 |
| NCT01804634 Reduced Intensity Haploidentical BMT for High Risk Solid Tumors Single-country: United States (3 sites) Decision brief → | Ph2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | recruiting | 2013-03-05 | 2027-01 |
| NCT00840047 Methionine PET/CT Studies In Patients With Cancer Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2009-02-10 | 2027-07-27 |
| NCT00788125 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | City of Hope Medical Center | terminated | 2008-11-10 | 2010-04-30 |
| NCT00186992 Radiation Therapy to Treat Musculoskeletal Tumors Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2005-09-16 | 2023-09-15 |
| NCT00077285 Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | active not recruiting | 2004-02-11 | 2027-10 |
| NCT07888114 Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities Single-country: China (1 site) Decision brief → | Ph1 | Beijing Tongren Hospital | recruiting | 2026-10-22 | 2027-03-31 |
| MRG003 · NCT07584499 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors Single-country: China (1 site) Decision brief → | Ph1 | Sun Yat-sen University | recruiting | 2026-05-13 | 2027-05-30 |
| INTERCEPT · NCT07224568 Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | not yet recruiting | 2025-11-04 | 2030-08 |
| NCT07222735 Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2025-10-30 | 2030-11-05 |
| SABRE · NCT07172958 Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) Single-country: United States (2 sites) Decision brief → | Ph1 | Children's National Research Institute | recruiting | 2025-09-15 | 2041-12 |
| IMPACT · NCT07148050 Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | recruiting | 2025-08-29 | 2029-04-22 |
| NCT06865664 FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma Single-country: United States (1 site) Decision brief → | Ph1 | National Cancer Institute (NCI) | recruiting | 2025-03-10 | 2027-12-01 |
| NCT06566092 Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants Single-country: United States (5 sites) Decision brief → | Ph1 | Iovance Biotherapeutics, Inc. | terminated | 2024-08-22 | 2026-06-19 |
| KinLET · NCT06441331 Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors 3 countries, 56% of sites in the US Decision brief → | Ph1 | ITM Solucin GmbH | recruiting | 2024-06-04 | 2028-06 |
| NCT06198296 Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | recruiting | 2024-01-10 | 2028-02-01 |
| NCT05857969 Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling Single-country: United States (1 site) Decision brief → | Ph1 | Florida International University | recruiting | 2023-05-15 | 2028-02-22 |
| NCT05429502 Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors 4 countries, 50% of sites in the US Decision brief → | Ph1 | Novartis Pharmaceuticals | terminated | 2022-06-23 | 2025-02-26 |
| NCT05210374 Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas Single-country: United States (1 site) Decision brief → | Ph1 | Case Comprehensive Cancer Center | recruiting | 2022-01-27 | 2026-09-01 |
| NCT05103631 Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | active not recruiting | 2021-11-02 | 2025-01-13 |
| NCT04995003 HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | recruiting | 2021-08-06 | 2028-06-30 |
| NCT04897321 B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2021-05-21 | 2027-03-01 |
| NCT04715191 Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | recruiting | 2021-01-20 | 2027-08-01 |
| NCT04483778 B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2020-07-23 | 2040-12 |
| NCT04420975 Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Jonsson Comprehensive Cancer Center | active not recruiting | 2020-06-09 | 2027-01-31 |
| NCT04377932 Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Baylor College of Medicine | active not recruiting | 2020-05-07 | 2024-08-17 |
| NCT04337177 Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors Single-country: United States (11 sites) Decision brief → | Ph1 | Valent Technologies, LLC | active not recruiting | 2020-04-07 | 2026-12 |
| NYMC195 · NCT04308330 Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Single-country: United States (1 site) Decision brief → | Ph1 | New York Medical College | recruiting | 2020-03-16 | 2026-12-31 |
| NCT04299113 Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma Single-country: United States (1 site) Decision brief → | Ph1 | Jonsson Comprehensive Cancer Center | active not recruiting | 2020-03-06 | 2026-12-30 |
| NCT04084067 Indocyanine Green (ICG) Guided Tumor Resection Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | completed | 2019-09-10 | 2026-07-28 |
| NCT03635632 C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Single-country: United States (2 sites) Decision brief → | Ph1 | Baylor College of Medicine | active not recruiting | 2018-08-17 | 2023-05-16 |
| NCT03618381 EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2018-08-07 | 2040-06 |
| CLOVER-2 · NCT03478462 Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas 3 countries, 75% of sites in the US Decision brief → | Ph1 | Cellectar Biosciences, Inc. | active not recruiting | 2018-03-27 | 2027-06-30 |
| NCT03054792 Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas Single-country: Canada (1 site) Decision brief → | Ph1 | The Hospital for Sick Children | enrolling by invitation | 2017-02-16 | 2026-12 |
| NCT02508038 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1 | University of Wisconsin, Madison | recruiting | 2015-07-24 | 2026-12 |
| NCT02013336 Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors Single-country: United States (5 sites) Decision brief → | Ph1 | South Plains Oncology Consortium | recruiting | 2013-12-17 | 2026-12 |
| NCT01858168 Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma Single-country: United States (5 sites) Decision brief → | Ph1 | Massachusetts General Hospital | completed | 2013-05-21 | 2024-11-01 |
| NCT01625351 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | completed | 2012-06-21 | 2020-02-10 |